TMO - Earnings call transcript Q4 2018 | Thermo Fisher Scientific Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2018 Fourth Quarter Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] I’d like to introduce our moderator for the call, Mr. Kenneth Apicerno, Vice President-Investor Relations. Mr. the begin may you call. Apicerno,

Kenneth J. Apicerno

thank Good joining for morning and us. you

President is call XXXX and expectations press our Web Vice live Officer. and XXXX. with the being A the archived X, section call available Marc Presentations note until release our Stephen Investors our Chief this Please site, me Senior of will Officer, On February webcast Executive section of thermofisher.com future Results. today Casper, under the Web our the is heading earnings fourth Financial Chief the in President Williamson, on be site and quarter Investors of is heading Webcasts the and and of copy and Financial under

Harbor Company's we make under Litigation factors, statements is as the and quarter those under Harbor may XXXX, in available result those Exchange of Web the statement. indicated of Various heading Before XX, the by expectations, let section and future for materially Safe ended XXXX. our Securities from Actual we constitute important Factors, for Quarterly begin, including remarks Form site with about the forward-looking purposes various may Safe me of forward Company's statements September the discussed in Filings. the Risk provisions caption is and also under on these Report Private on file a our briefly prospects plans which the the XX-Q Commission Securities the looking differ Act of that Reform results cover Investors SEC

fourth to our change. our statements Also referring these the measures disclaim we these reconciliation section in expectations in during also financial principles measures and call, rely most not press measures to be is the Financial or accounting so point of to quarter A Therefore, in our certain financial not heading subsequent we do accordance prepared GAAP non-GAAP GAAP. you Web the directly today. views available any at future the to forward-looking XXXX future, estimates statements Investors should if our with to obligation of under elect site comparable some date of representing of may Information. While even earnings the any in we'll as as specifically accepted update generally forward-looking on and the release

that, So, turn the with I'll over call Marc. to now

Marc N. Casper

Good everyone. us morning, Thank today and you QX Ken. joining XXXX you, for for Thank year-end call. our

we report exception. As growth long momentum you excellent delivered the that release, to growth the saw year on We quarter delivered We're our all pleased very we no year. and year. was QX press had both strong fantastic a and in

executed advantage good team well to across in conditions our that end the of Our markets take continued XXXX.

the and gain speaks to of to success our to Our our continue our strategy performance and ability position strengthen growth share.

scale products, to created commitment building advantage has launching proposition Our enhancing value new emerging for in in a competitive high-growth markets, us. customer and great our clear

reducing and effective customer shareholders bolt-on We to We returning with strengthened also our growth nice strategy. complement two completed while to debt. capital an capital acquisitions offering continue deployment our that our

very year-over-year EPS in XX% strong expanded to high-level. operating income margin from up performance to but billion per We QX billion. adjusted delivered remarks, to further a in points in in our success. I XX and increased X% increased adjusted growth QX outstanding the sets and has a will $X.XX hit $X.XX XX.X%. $X.XX quarter to revenue with XX% the our operating Our first Adjusted increase I at our with XXXX basis share. will some Starting later my the us the for in the position highlights leadership quarter of strengthened cover financials and year quarter, long-term the

$X.XX XXXX. the results Turning Adjusted with billion, $XX.XX operating in XX% adjusted by XX.X%. XX% billion increased to revenue for to of margin increased We full-year. our operating to income

We adjusted in performance per in to XXXX especially a with share. deliver $XX.XX another XX% our pleased increase earnings are EPS strong of year to

Our the power excellent even our make is earnings well that of continuously Business PPI better. executed effective System to we and growth deployment the leveraged a growth capital our strategy, combination better of

is all and well a that up for sets So us fantastic XXXX. by year accounts

turn performance I'll Now to by end market. our

As outstanding we our leveraged to the year. growth. board conditions I what proposition mentioned, we all remain with strong drive value effectively consistent across customer saw And

me some color. Let with provide you more

can share. strength unique and in growth the this We depth our advantage these teens us So Pharma market. of end all continue in clearly and to businesses starting us low with the we quarter continued we delivered gain is customers offer of serving and an Biotech, capabilities allowing giving see to to

performed in for and mid-single and across digits In in well. full-year. position see teens led And channel QX. during solutions Our great the it academic demand also Pharma our instruments in the to and grew growth government, analytical and mid year. strong the the science our research the We for Biotech was to leading quarter businesses life continued

healthcare, we Turning in full-year. the transplant clinical diagnostics, and for both digits for mid-single QX. grew diagnostics businesses quarter to in diagnostics and amino this and our In the good growth in we the diagnostics had end market,

quarter led businesses. Finally, analytical performance strong our XX% industrial applied, during and we by in growth delivered across instruments the

in grew we full-year, single the high digits. the For

and end the performing high on really capitalize unique our level saw capabilities we leveraging markets. scale opportunities of to across a at depth So and we’re our

very continue We that our bodes strengthen for and our future. to well position strategic

our a strategy. continued the strong and in with product our innovation the all let committed you in in innovation, across our difference as and accomplishments our of We're strategy, $X pillars strategy, Now new three invested launches to great discuss growth context XXXX. making for we of billion portfolio. see really our high-impact of We're pillar our across first progress in momentum our customers, of me can we Starting that's making results. R&D our

return the mass In spectrometry microscopy. a that analytical I lineup to impressive strengthen instruments a of by continued getting our year, our Thermo chromatography, on across and we building will Our new investment. and that our leading business, great products electron on of shows our growth Scientific brand highlights. recap revenue platforms we're the during strong few

early In fact, of that from examples working launched XXX Tribrid a value are the Exactive at food as drugs Scientist came readers XXXX, Fisher. electron top that Q mass them GX Q franchise, of systems that by markets or the Orbitrap whether In magazine's such year that discovering in the Verios our innovations the ASMS new scanning list in customers applied create we through our we in and in Orbitrap launched Thermo leading safety. our microscope business, our electron launched the the microscopy up is in are made we strong of is Science of sciences continue ramping XXXX. adoption gaining XXXX spectrometer And is top our customers. began the IDX to to great from quite we UHMR R&D tremendous and it's And Glacios Materials Magazine, were customer seeing traction with which Exactive the five customers. see The feedback shipping Analytical XX that we HF-X These reinforce positive. innovations good for life Cryo-EM year-ago nicely, recognized our

in we and the in highlighted start. a solutions Ion off Torrent GeneStudio business, Turning our is launched we microscope Invitrogen XXXX, of with QX, for to to our MXXXX benchtop strengthen instruments to EVOS sequences very Next-Gen SX line life imaging continue that good digital of series our science cell

business, B·R·A·H·M·S two autoimmune we and immunoassay benchtop instruments specialty KRYPTOR help to our automated Finally, in the and doctors launched XXX GOLD in diagnose diagnostics conditions. system important XXXX, Phadia the analyzer allergy

to look excellent our clearly forward innovation continuing for year we XXXX. in an and So momentum

emerging delivered growth had high-growth to about Turning only represent performance broad-based geographies, again to the effectively reflects create in do our in XXXX India. in second including our we’re we These $X our growth double-digit of pillar total in growth leveraging markets, excellent we China, In revenue advantage. markets our or now growth these not strategy, billion. how but competitive of strong XX% scale

me spend a is minutes outside Let market know you on our China, which as U.S. couple the largest

business led year. to from another a our in in Our for benefiting build, We're the had scale strong than experience XX% and which customers. We growth the to there market. team continued our grown to the us we’ve deliver has clearly to that allows quarter faster that China differentiated QX consistently

located we bioprocessing Design collaboration high-growth our opened in Shanghai, This center in Bioprocess goal solutions biologics technology. particular, in and latest center own that we In to to design market. facilitate application medicine two this centers is The Cryo-EM. and scientists which our bioprocessing you opened our features and customer in XXXX, recall commercial in a and demo in gain. infrastructure, In share may Our China in established XXXX, customer we growth to customers commercial between advances strong training new November. also driving our precision is new and optimal showcase for is Center our capabilities office Beijing, first

we’re capabilities our we continue scale China about the of in to customers, XXXX. of We meet increase and into the needs have excited going to opportunities depth and our

Our enable healthier, to to and and from national our supporting the focus customers aligns company the mission safety, continued confidence cleaner comes environment priorities food China's health, with public directly on our make world which safer.

our unique our show pillar and offer, innovation And capabilities enhance strategy help new The our customers our What's customers growth meet it's goals product to of important that comprehensive can and is productivity. we value our And proposition. can by to the the our here a delivered benefits that that provide. their we we innovation results third unique product really whether more for continued value we leveraging that is value or offering. services customer

quite And use growth in faster been the our mid-teens. Let Pharma an to for example. customers XXXX here significantly growing time. as and Biotech some our We've than market accelerated the me

a of we’re capital strengthened reactions Our incredibly large The integration growth, and Patheon these in emerging been that well and pharmaceutical and strong of the they’re offering in need strong of business the are given smoothly. further the was gone to increase August small strong efficiency. whether commercial The XXXX. biotechs it's very delivering capabilities that that our have don't Customer great performing position acquisition seeing. in-house or customers momentum has through customers very capabilities Patheon positive for have we

our capabilities increase market, deliver [indiscernible] sterile We and trial and expansions Germany, St. serve to on Rheinfelden, facility Production this Center in to targets synergy clinical Louis in $XXX on North synergy Italy the From in our our chain of million. we’re [indiscernible] including our a attractive Carolina. of perspective, our supply continue track to Biologics

Our impact PPI a System positive significant on this business. Business is having

done, to our Pharma Services the the seeing clearly are There's good much excited have we're the about up results. we committed based for wrap partner we our to progress leading be To be very the business our So possible still outlook and more opportunities through strengthening date. this feel to but we our strategy offering. best we're position customers, for on growth to discussion, our about

record track of for great in a we have we being XXXX. by know creating shareholders you continued good as value here capital stewards deployment, capital to and in now Turning our that

following leverage is reduce Xx the First started We acquisition. debt our with billion. leverage to ended just we balance our $X and the goal sheet year the over by reducing debt to with after year Patheon Xx strengthen

than billion [ph] Second, bolt-on the $X.X more on advanced customers. business portrait largest we which of a Biologics a The Becton closed was our that QX, deployed two in bioprocessing self a products we for production little acquisitions. added complementary Dickinson

which our by into the time you continued work of to the stock incorporated additional to close to buying in regarding to our Pathology over put Stephen details shareholder we here, year comment of capital remarks. which dividend his sale XXXX during back more to versus value. $XXX -- will guidance. Monday return us transaction work expect saw last will Once XXXX. our XX% business, we our on announcement give also Anatomical during give put One you and is We QX, million shareholders our capital increasing the create

QX was very performance, deployment year To perspective from capped fronts. fantastic a it well. a our strong off year summarize really productive on So all capital as a our

strengthened to Our team growth. executed and our our continuing gain very growth leadership revenue and strong well industry advancing deliver earnings to share. strategy We by

our customers our to deployed value significant capital effectively also shareholders. our for create We and

extend the to outline will consistent cover a the and financial as XXXX. ahead Stephen track earnings but and guidance, into our record revenue you of quickly that performance in would factored long expect, planning highlights. Looking assumptions let we're strong me

result In of which in X% revenue we will $XX.XX This X%. to our to to adjusted billion revenue EPS would We're deliver to in of range reported initiating terms for per to XX% $XX.XX XXXX a the lead billion X% growth guidance $XX.XX expect guidance, of XXXX, year-over-year. growth and in between share. $XX

our Our now outstanding really Stephen ahead. CFO, XXXX I over us successful for will that, hand results call in sets to With the Williamson. year up another Stephen?

Stephen Williamson

color the Great. begin and XXXX conclude full-year and four for will quarter provide fourth some total morning, our with good I review our Thanks, overview everyone. company. will results Then detailed a an our I of Marc, and with of segments on guidance.

get into to our our how I would fourth the provide expectations the financial high played level Before thought I the a earnings performance, it quarter the at of be time details of versus call. out of view last helpful

less FX an driven strong by EPS than higher we the that adverse delivering growth adjusted As release, to earnings execution organic delivered to our From press by great through guidance. had is gains. in strong we our you by continued organic the saw This lesser QX on is $X.XX XXXX, the conditions, standpoint, in X% previous environment. growth of for strong a and share operational full-year. was This driven market and and degree continued midpoint finish a primarily pull

growth, full-year and in adjusted excellent growth Overall, earnings XXXX. in XX% X% income, growth operating For in XXXX per delivered financial organic adjusted XX% share. we results

let on our our results, more Now as to by you $X.XX. press in earnings give performance. QX XX% release, EPS me we with adjusted in saw grew color Starting you our

XXXX; For XX% year. EPS the in $XX.XX, QX $X.XX, the the EPS versus GAAP prior and was XX% quarter was up XX% up GAAP adjusted XXXX, versus EPS full-year, $X.XX, was for up the full-year, from

foreign approximately the grew our and approximately of revenue our On year-over-year. QX organic X%. headwind growth included revenue X% top reported increase QX X% line, The X% of from a growth, acquisitions, components exchange reported

revenue This include X% organic and year-over-year. acquisitions, a increased impact growth, X% X% reported exchange. XX% foreign benefit an For from XXXX, from from the contribution full-year positive

in Looking in grew at teens, across quarter the Asia-Pacific in another growth both grew mid-single by growth the very the QX. of strong in high single geography, of rest our in markets Europe were and the globe digits, strong America North the including digits. grew and China world low

grew the single For rest the of grew America high world full-year, Europe in and the grew Asia-Pacific the and mid-teens. digits, in North mid-single the digits, the in

XX% good margin feel performance, by Turning basis from Business volume and increased adjusted our was operational our QX to QX year. last System from of income offset business points investments contributions We strategic XX mix. strong and PPI operating adjusted XX.X%, productivity and up unfavorable operating partially

which than is and increased our We feel PPI was full-year, XX contributions. the And income operating strong For adjusted volume basis XX%. points lower adjusted from System good margin operating XXXX. XX.X%, productivities Business

the However, this of impact business by was more and strategic than unfavorable acquisitions, investments offset mix.

down P&L. details quarter offset Moving at in unfavorable mix onto the the of margin strong the through from XX.X%, In Total company adjusted in and pull on more volume business QX by year. was gross basis productivity quarter, points than XX prior came investments. strategic the

expense XXXX, as QX And a a reinvest was businesses. revenue the flat to in which and impact was down strong points is versus gross was was volume adjusted line R&D mix, than basis margin of full-year, by strong revenue, business we last from X.X% of Adjusted was strategic of investments. through X.X%. pull full-year for at basis R&D total of came our productivity XX.X%, the the a compared XXXX, to by down year and in more manufacturing offset the For percent quarter driven XXX continue revenue, our X.X% XX.X% QX as in acquisitions, growth. points SG&A unfavorable QX top of in XX

for higher of primarily $XX XXXX, of changes million repeat to net At income FX. QX $XXX interest for we debt than In million, Looking foreign we driven improved from in income a other was results lower was XXXX. increase QX $XX benefit Adjusted nonoperating million, in in due at our and nonoperating a whole, the Net this expense net of the expect income full-year XXXX. majority down not of do as million exchange. this XXXX year, expense of below from level primarily quarter, point saw $XX $XXX interest and quarter last interest the million the line million from income. expense by was an a $XX to

with Our guidance. last previous quarter the in QX were basis our line year down adjusted XXX versus and tax in XX.X%, rate points

tax shares reflecting U.S full-year shares XX.X%, is impact Our adjusted lower the beneficial tax higher basis QX was average full-year year-over-year. XXX million, were of a points than primarily diluted million X.X XXXX, XXX rate reform. which

XXX up average For diluted million the XXXX. full-year, shares million, X of from

balance to flow sheet. the and Turning cash

cash full-year, from and the $X.XX million. was flow For continuing $X.XX operations billion of billion net free was after $XXX flow deducting cash expenditures approximately capital

post our of to focus acquisition was XXXX primary the reduce flow of cash Patheon. for Our debt use in

billion Our debt the billion, year. total the $X at prior QX $XX of end was down from

the down debt cash. ratio approximately and down rating. to demonstrates with year leverage EBITDA, our this ended X.Xx Patheon total adjusted the was point to maintain end of $X.X at in from strength commitment significant and the from at cash investment-grade our X.Xx acquisition. solid the last Our post the debt a flow immediately of quarter billion This Xx We quarter

we to buybacks XXXX, also returning million million share and During in shareholders of $XXX with dividend. $XXX continued capital

mentioned, proposition Marc of up was ROIC our our last returns. from In we To basis capital value acquisition up as from to strategic year company quarter to Bioprocessing. recent deployed very strong last Advanced successfully points QX and addition, XX wrapping basis my and adjusted comments including we customer as up XX.X%, XX our strengthen performance, total points continue acquisitions, through generate

reported and Now growth X% Analytical I the strategic quarter, of revenue saw business we four performance the X%. quarter, continued and strong revenue quarter, see Solutions. color was the and operating the see In good in mix. income operating increased XXX life basis XX.X%, XX.X%, the In increased to the this all you drove in businesses. growth was positive will Science for volume and operating strong provide This Life adjusted with science QX, XXX grew bioproduction, margin XX%. some was productivity leverage, and year-over-year. investments. clinical from solutions revenue organic biosciences, very the on offset pull-through, In volume we we points reported the In segment segments unfavorable businesses quarter, led with investments. Analytical starting points which in growth segment our by QX and XX% very to XX% In the by a was in benefited also of year-over-year. XX% our segment, the In operating margin increased in by adjusted segment. quarter, QX sequencing partially continued growth up strong was is adjusted revenue offset organic acquisitions and basis adjusted the income QX and we a business impact productivity, partially mix, very across of in Instruments up business Instruments good next-gen strategic

Adjusted Turning total basis this Growth we QX, segment revenue diagnostics and X%. to diagnostics, year. adjusted quarter X% in businesses. the points leverage. income prior growth by was volume neuro organic the was margin was good operating and decreased down from clinical In segment, in led saw transplant Diagnostics operating Specialty in QX XX.X%, and diagnostics, X% our grew revenue XXX

by this offset investments than unfavorable business mix. strategic more and However, was

segment in revenue increased initiating includes sale we basis of quarter, Adjusted quarter, points. guidance. $XX.XX, operating and by volume XX Laboratory the and the XXXX we week. Products was saw the adjusted increased of the across our growth a business in Pharma that dilution This Pathology net This strong the the and Organic business. details offset Finally X% $XX XX.X%, which businesses leverage. of was reported in we business partially With which In was I the productivity and XX% the prior that, is by higher X%. margin announced year to from XX% to review strategic Services range the EPS We're good Services Anatomical X%. like than this income operating investments the XXXX adjusted our segment would led XXXX. earlier In over $X.XX to by of guidance growth segment, all QX was growth saw revenue mix.

$XX.XX which In billion, terms over is of X% growth to range billion revenue, of X% our to guidance is XXXX. $XX.XX

factored into key now that XXXX the our me Let guidance. assumptions we full-year cover

in growth of this EPS revenue $XXX headwind are expecting or assuming We X.X%. the [indiscernible] With to regards that and $X.XX The million in FX, we X.X% majority XXXX deliver adjusted in headwind or of to of XXXX. X% the first organic year. is approximately expected of are half of year-over-year revenue

of you As of the to business. million I this which business through In sold approximately guidance $XXX mentioned, AP divestiture $XXX Anatomical the had Pathology I revenue million, referred business, our channel reflects as XXXX, of our approximately was businesses. the which

income. to divestiture. impact business. through are transaction the year. a sale EPS retained year-over-year be We AP to assuming deposits of products we of the in in flow of approximately and million. will channel closes are expected $XXX QX. free to calculation fees of and would we're are will assuming the continue cash net of In the This of that the on our be and million placed the XXXX, for of Both The create the of headwind the revenue $X.XX $XXX cash these related our estimated after proceeds reflected net write-off adjusted million To $XX remainder taxes the dilution are sell impact, channels These adjusted sale XXXX. headwind approximately income interest in operating the earn transaction

in XXXX million This our the completed to reported is be $XX to of acquisition Advanced acquisition the Bioprocessing. principally XXXX. will approximately contribute growth expect We from in revenue

tariffs assuming includes are currently approximately change of from impact are of is tariffs the environment in XXXX. that EPS reflect gross year-over-year our $X.XX in $XX means annualized million that We This of the there trade headwind place. in tariff the or guidance to full no the adjusted that

the of AP on basis offset basis to adjusted headwind of XX from points operating sale the we assuming expansion and year-over-year. deliver XX Turning business that are the margin, point we a tariffs

level and partially higher cash interest in of lower balances, offset XXXX, is by to we $XXX assumed be This rates. the million. billion line, below and net debt higher than Moving driven expect interest XXXX we is lower debt $XX are $X.XX about average approximately and expense assuming by repayments million

lower net in below will million XXXX FX income are XXXX. is $XX line to million, that be which other due $XX benefits about We than the assumed assuming lower

improvement rate to that expect We tax U.S planning tax from XXXX XXXX of finalization the XX.X% in The reform. adjusted rate our be initiatives to primarily tied XX%. reflects income tax our

the expenditures are This $XXX We assuming to of capital XXXX, be bioproduction capability is $XXX represents to expansions capacity Pharma investment year. approximately and Free The for million increased net an million between be million driven $XXX million flow expected and by primarily in XXXX approximately by increase expected our in is cash driven over Services businesses. XXXX. to $X.X strong earnings growth. over

capital future share we are assuming approximately million, assumes share this assume our any any divestitures. of AP terms not to the of $XXX guidance exception future of this that and and estimated month. approximately million earlier were in return of capital guidance be average does to we acquisitions through assume business, XXX does We a In full-year sale $XXX shareholders and completed with diluted guidance which million deployment, of that of year XXXX, dividends our not buybacks the total will also the

Finally touch phasing to I on for quarterly year. the want

the In expecting lower level QX we terms quarters organic average, but the three are same of is revenue are other of that than about growth, the yearly growth.

are total of you we as of EPS, at adjusted the percentage expecting of year. look the XXXX terms each phasing same In quarter when a

performance. underlying to summary, business. AP XXXX of back call guidance adjusted EPS growth and is of EPS level, over high X% FX the the I X% the -- our we in with the headwind will financial continuation XX%.In growth. X% is in a So adjusted the The XX% at growth the the And turn EPS strong and to reflects growth organic expect XX% from from revenue Ken. very of to deliver Embedded approximately sale adjusted XXXX, to that,

Kenneth J. Apicerno

Thanks, Stephen. we're questions. ready Operator, to take

Operator

Instructions] from comes first with Tycho Peterson question [Operator Your JPMorgan.

Your open. line is

Tycho Peterson

on meaningful I Hey, on It a the Pharma. of any synergies guidance maybe terms how just then that’s embedded up Louis St. in about the thanks. again double-digits to what’s And for there Congrats update this be expansion driver growth pay in Obviously, could you. want customer been kind you revenue year are of quarter. for start Marc, such down [indiscernible]? on M&A? feeling and and

Marc N. Casper

in good organic Tycho, full-year. We're with for terms assuming year growth Sure. and the the morning. X% thanks of

We strength value in embedded market are assuming Biotech customers. Pharma high resonating of guidance how the the single-digit proposition with end is is on the based and well and in growth these our

expect the continued share gain. year We of

you those the terms consolidation, because are synergies that we given that are looking customers consolidation very know, benefit unique from In of as typically and going of part to And creates are synergies the about those the good and we’ve bigger thinking of we capabilities some getting meetings that much customers. with industry for delivering the that companies had already forward. opportunities we have,

the a expanded future. of really be are trials our excited Louis end terms that St. wins has capabilities Pharma Thermo towards well we we And from very the of year, that acquisition, the our expansion, receptivity to call our it event that our a set should expansion. which timeline there customers have Fisher Patheon In strong is bodes Services, for XXXX completed for and commercially revenue the the extremely beyond historical clinical of business, so and

Tycho Peterson

can follow-up, really guidance for are just decision the know nothing I you slower embedded growing comment then sell Anatomical Pathology? a in other to just [indiscernible]? of you And in Was business it for looking a being additional on a Okay. noncore? at there's And function divestitures?

Marc N. Casper

at for business AP as Future have good good And Fisher of job time. Anatomical contemplating this know, of the Pathology transaction the is as so really the any that point Thermo is we're for value. shareholder management And both to and that think Tycho, we we you create don't business. team the our divestitures Yes, a other

Tycho Peterson

Thank Okay. you.

Marc N. Casper

Thanks, Tycho.

Operator

Evercore comes Muken ISI. question Next from Ross with

open. is line Your

Ross Muken

and Good guys, congrats. morning,

the year you this of seen that month-on-month this any obviously it any that in and huge of XQ sort the phasing early for pause anything you gives China, parts up orders, of thinking of picking I of how just you. Marc, sort business maybe, about continues you So of a to end business? but the progression guess, in of whether of year a be in into [indiscernible] lot are strength have headlines, or from perspective

Marc N. Casper

Yes, Ross, question. the thanks for

of trend environmental of focused as healthcare China, year, X-year And of and for and strong quality In China years. protection food really plan expansion terms strong life of reminder, very on improving an really improved a many a is China. very the continuing very safety. It's creating within

strong our team person in in is there outpace the market on position, leadership of how We underlying what's of and spend and QX of XXXX capabilities because the also of in growth. -- phasing terms Orders terms year. with the for throughout the competitive are China market and going in we’ve first they’re was quite very about the week our to The customers our did pipeline market were of unique good. terms time of January the our strong demand prospects continued in bullish So both perceiving the and momentum. in within

growth XX% looking I’m quarter China strong the So a with to very organic quarter of forward customers. end this for And to team going well, spend and at to fourth orders. the year, as time good our

Ross Muken

post revenue year deployment about it just guide guide from it. know you’ve got given buyback, year closed the is substantial and as now. the your some time? balance in focused in M&A warchest is wise? a follow-up are maybe seems from more but second just just [indiscernible] mean, secondarily, capital And of Pathology should you not assuming I'm we accretion Thermo that in in then given pretty of in capabilities Gatan a I on what you the of the on the the terms of sheet you’ve with we And sort bigger sort prior How M&A. thinking think quarter, got sort clarification this on like then or sort have had one of that guessing expectations Excellent. for and commentary practice, contemplated Anatomical I

Marc N. Casper

Gatan, terms that of So, in have our Ross, results. we don't in

So that our that year. back will is half we soon do as as it closes close in that the will this of and expectation

you as to that long-term over Anatomical time. as and the and timing focused time know primarily will deployed over In strengthened terms will of the M&A. so as the capital don’t capital know deploy over on assuming know buybacks we us doing capital disciplined, deploy on to capital. And the and give done return incredibly for the in model balance deployment, and we're us do spend the particularly X-year Pathology substantially to year. even more for sheet Stephen And our shareholders we model, said, we our of you From you firepower our not we’re perspective, in continue value deals and the and we've create we're see right time to awareness we M&A,

Ross Muken

Marc. Thanks, Excellent.

Operator

Lynch. Next Bruin, question of America comes Bank Derik Merrill De from

line Your open. is

Derik De Bruin

Hi. Good morning. questions. Two

improvements did a than a the Thermos. sort I’ve Patheon, the follow-up. done was the be the margins one the the what and now Can first you about bit you I The one fact talking on lower then on of in business transaction were when of concerns business Patheon quite talk about the would that you’ve margin margin one? is gross where operating that And think

Marc N. Casper

have we different growth Yes, And business. really mid know, so -- you business, was of our from in type one a the year two is as acquired the where in single-digit things. we when Patheon business, focused it kind

first business. The step that year momentum. that XX% grew to see the the to was momentum is just for It and which in business we about that in really of accelerate up of nice

So that first. the was

and across to is the a impact on network The PPI apply huge was having widely second margin. that

in margins are the we now. mid-teens So

they’re that the in higher trained is that We that when do expansions the our you the slightly of in you capacity couple to quality will for expect so And a in production [indiscernible] can increase in you reason large online, year. we that when and we're Louis advance and that people benefit. have this so comes get St. and doing actually advance finish be network, the

and So nice future see year, you would forward. that expansion in similar the this very be will going then you expect margins

how are would that's think So we about the business. where with I Pharma Services

Derik De Bruin

QX, Great. and then had And the on in Brexit and market moving government government I the should and the you given and just do in little shutdown -- we've follow-up going academic we’ve obviously parts? we the conservatively the U.S., more that government I got a some bit market. shenanigans think mean, other model on. all what a guess, about some academic

Marc N. Casper

Yes.

seen strength would the single-digit academic single-digit attention in paying So guidance to mid in market. is are We've government. low we Europe. year XXXX obviously and growth just what to for China. We good the embedded say growth more single in mid I a on had bit is for And our in what in is little

funded of government As or the XX. you know, is funded XX% U.S was through September

NIH that's wider reasonable are that should to But for we Europe, of the outcomes be ourselves important thing attention so for we little for the the outcome year. year. year. a between looks range most giving and bit this was So good been fine mid and low and feel we’re so paying And a just

Derik De Bruin

Thanks.

Operator

from Cowen. Doug Next Schenkel with question comes

Your line is open.

Doug Schenkel

morning you long-term regarding My one X%. to Hey, for thank target questions. first X% and my of organic taking guys good revenue is growth your

was above You well in grew that market XXXX, helpful. clearly

would it's the If to it to versus of much We in in range of I growth are and That out was growth long-term the being normal the might three maybe end that, generating in I point You your the successfully. if your range breakout assess strength portfolio playing how us. strategy said, of at try the the be of evolution the execution? than that pillars the better end wondering growth to willing possible how you help future? markets strong increase higher XXXX your you answer walked was sustainability through would you some possibility think versus

Marc N. Casper

Yes.

for and So, Doug questions thanks the morning. good

a growth a we a after the year at that and to actions a to you synergies mid Patheon the low meaningfully market business we single-digit as the team. within half model, by acquisition, from business about the we're X% driven technologies Meeting have more grow look XXXX the the the the clearly revenue doing for the the is during As right? FTI, I the as a what market. at taken X% things on of faster taken life Analyst and accelerated in said least we're year, more assumed than high was invested and really see of a think the higher things and the That’s the So When driving is you long-term as ton at to our we’ve sense through strong. fantastic portion May our know get gain assumption. businesses we’ve in of guidance, we’ve When we’ve strengthening the long-term course to changed and mix of to that high-level the because one that you growth And historically. businesses we the we’ve was of owned performance, our adding close, the the sort market value to acquired the a I of company point share we've execution we as

years in So -- year point strongest the X% starting and the many I could is point remember the starting of start for actually the company. our the that Stephen

model figure when So right bullish in the we look in the forward think out May longer-term back is about and everybody seeing will to at we're and posture New that very outlook what about the we York point. we'll

Doug Schenkel

XXXX. have over third quarter look quarter. year past this I X-year and moderates core revenue you growth And the difficult another Okay. of impressive, That's the year, a are X% really I X% an stack are assume comparison those XX, said, in couple at growth my is which logic up including helpful for your look actually around the down in stacked average against heading the Again, last tough second QX X% making on last then clear in into quarters core guidance fourth remarks That philosophy. one in to at if good and grew but in the plus to implied [ph] topic, is very 'XX. of think growth guidance that in in what and the X% to sure 'XX guidance segue against still would X.X% get growth rates couple the to comp just Europe XXXX, or rate you

the in suggests it's markets end You everything things end January? the the not make sounds great. geographic that really if over comp market. just anything fair to it's to upside that you trends several execute have function biases just anything or make I way that want is sure geography still and that last to missing and we’re are the to fact the that guidance the conclude slowing any the want and continue certainly you that haven't of Again, and continue, just sure I to underlying said years.

Marc N. Casper

Yes.

So thoughtful. very

I to you at get what our As you momentum, a So be XXXX versus the and XXXX, in customer sort pipeline, strong. have the fundamentals actual When that our bit associated uncertainties growth order is you underlying Brexit like start. look assumed more in think GDP initial trade look of slowdown not but seeing wars, will in because that we things at assumption very the slower a the guidance what's about could right? that's is right? the business, year, world contemplates So challenging, guidance and within the our of actually book with it's are

have fantastic, this conditions and spectacularly year a year will So as couple that's this slower how a year we be allows times and of last if and bit with course the Stephen half, us be I will we’re year guidance the has this over said outstanding thinking enjoyed happens. be of last the GDP market a as deal that if was know. an last year, fantastic, stay -- if about during the don’t just to But it'll growth

Stephen Williamson

growth of of remarks. my Yes, in [indiscernible] as kind year I organic phasing for described the Doug, expectation prepared

Doug Schenkel

That’s great. guys. helpful, Very you. Thank

Operator

Next question comes Jack from Meehan with Barclays.

open. is line Your

Jack Meehan

you was can FTI customer what that outlook morning. this Good per the in assumes overall I elaborate and on various across growth hoping for classes the your outlook year business?

Marc N. Casper

Yes.

thanks question. for the Jack, So,

growth growth have So of accelerated prior our business, of to as because a And outstanding we've those microscopy And year. you of of material acquisition. at that strength added single-digit really low the reminder, we the value business portfolio. business sciences, the electron the had another the are look when how combination to

the in in the difficult we year, have that you adoption electron launched particularly of XXXX half has of we the second that market because that and Cryo-Electron to the in know to assumption lead unfold industrial assumption our our product look given growth. it and the business that have and in When has a of half business, growth started bit growth and in as contributed will second visibility good. applied our obviously end Our year. We’ve strong But of microscopy also a the six actually will we looks and the outlook PPI good times Glacios is the business the Business in we're System will slower strength or about for whether moderate the shipping difficult on demand. the of not. we that that of because improved quarters more spurred assuming months the life very fact been comparisons, of competitive, has has their sciences the has made comparison the Microscopy a factories know And application spot additional was of and

Jack Meehan

Specialty Then you as margin was Diagnostics in and for a hoping growth. could follow-up, on the implications weigh I Thanks. the

those of think I those mix about think investments it's talk in can you of or quarters moderate so, XXXX the been a where there terms maybe ramp talked are to strategic other we Cascadion do see expected margins we few and strategic start to to investments, and you’ve as some how turn contribution? expand and about and

Marc N. Casper

to then see little Steve single-digit opportunities. Yes, I equation. the about will the capitalizing of growth. done -- the of talk margin side has nice about job on Stephen mid to and a talk a about growth Nice

the are launched we feedback. could We And R&D on expansion. Europe menu a very on are customer in working product limited our release, get Cascadion -- teams we so hands-on

contributor there. we're XXXX, the excited Our in about but time revenue and that over longer-term is a assumption minor ramping

Stephen, want about to margin? you So, talk

Stephen Williamson

care to margin we’re we Cascadion the continuing can make another clearly tied good investing profile making of terms these investments this all across also globe so in segment. -- to growth economics Yes, regulatory some and for commercialization, that in share, investing making launch, health -- sure are the ahead investments the of infrastructure

the to versus be one I think invest -- of continue three. this but the lower appropriately, margin we about will this expansion will So expectations other forward, with businesses going investments expectation

Jack Meehan

guys. you, Thank Understood.

Marc N. Casper

Jack. Thanks,

Operator

Beuchaw comes Steve Morgan Next with Stanley. from question

Your line is open.

Steve Beuchaw

morning, everyone, the Hi. time Good here. thanks and for

less trajectory market point up of gains things bring to press already When have -- -- Thermo performance and sticks before, the really would more detailed Q&A is times like Just think. what of about been on brought in to sorry the a number that that bit but I the think about a the of I I on in share of relative couple a markets end little I’m that touched up way. a on is course of

maybe at maybe is, look of portfolio is even 'XX is you the share relative that, and me most gains So reason why correct better. you 'XX, certainly my think to basically or any -- trajectory acutely there stable about free informative on question as and 'XX the feel to

Just be the helpful gains? in you to share hear incremental from about embedded how plan the think growth

Marc N. Casper

the for Steve, question. Yes, thanks

about So gain about market share our the think it relative share think company, could right? I And when right? If it I it's to lenses, about a you different gain, very been area growth. of China think from the broad-based real few across geographically, a has

few growing our but it are in business, look much it mass line, than electron that the by Pharma very strong you you broad-based, see a the business, have faster gives market, a by production as clearly spectrometry business business, competition. microscopy sense or others, all we faster than it's a others. it or product look but or forgot I’m clearly you we when Biotech, you at at sorry and If said meaningfully you business our biosciences it gain. And grew chromatography bio very share end

than XXXX year market, go possibly we have and about obviously best at execute can meaningfully the they teams the outlook, very very the minimum did think and the about X% faster better to least they’re and a is in are out in going us. As good XXXX our for I and drive that and what's embedded prospects goal we our excited than growth that for

Steve Beuchaw

growth launches. the bit you that’s some Thank been that. one you're I of Okay. but point, for most of just that refresh on layer traction the could with a there? the you more that jump is existing cycle give the is new It in us the of Thanks little Can I more it's drivers a that’s Phadia in sustainability fine share Phadia one of [indiscernible] do the customers? with again. it How or incremental Do little gain a the And seem a about acceleration seeing line like bit top will think then if -- you And likely second for important queue. you back sense then a of onion the sorry, that that? half the you of 'XX. wonder think peel back of

Marc N. Casper

Steve. Thanks,

really, So growth. market. And a nice we large our the percentage business and a good had are autoimmunity very allergy business share, of

the really that we drives blood market. we business, effects really and the business help, all we and we the the protesting testing, In expansion asthma the So really to we’ve asthma expand importance and it's as of when we based around and do menu expands -- of the enjoyed from testing, allergy benefits test. from as growth about so the is of all is what the that growth U.S., -- economics having about think that's migrating skin particularly the market get and health care drives about of really the good patients our allergy

doing So that’s outlook the is is business for well. how we thought as that well and positive about business and very it the

Steve Beuchaw

Thanks again.

Marc N. Casper

You’re welcome.

Operator

from Sachs. Next Donnelly, Patrick comes Goldman question

open. Your is line

Patrick Donnelly

Europe. Thanks. the Good can signaling Obviously, you there in is data macro outlook maybe talk the growth. morning. through lower Marc, just

on. spending political like given disrupt areas system shocks You government you’ve tends touched to potential that the instability of have layered on with Brexit, like typically as

for helpful segments? be the just would hear to So different it there outlook prospective your

Marc N. Casper

Yes.

Patrick, question. thanks So, for the

guidance Horizon in and the is low in is embedded in sciences we're you When X% is at assuming important country that the be government look bit the to mid versus the last single-digit segments, little the single-digit we're by XXXX assuming and preserving that opportunity organic to life At to that embedded within So I government in growth XXXX. a weaker the growth. for for will good the their same of heritage Europe couple year. what the meet week -- the with and had ministers very funding commitment is guidance for looks It our point, exists year U.K academic strong. the a

the for reinforce growth actually government, -- but taking economic given the for a academic more are potential actions the of just to think So, reasonable I be governments and little a mute outlook bit muted.

We will little so pressure see more out. assuming that there, how bit there's are we that plays a

Patrick Donnelly

from healthy earlier still pointing competitors bioprocessing clearly Makes growth market, just sense. like that on talk this the seems just given in market one you week, through Okay. continued guys, And it's you driving the give drivers Can that the most maybe results is growth there, confidence is? the then of guidance durability and biopharma upside were segment that strong up. the you that the

Marc N. Casper

or very year from of more really strong reminder, business. molecules of filtration. and the bioprocessing small and the in have leader purification exist molecule that in you four don’t bodes a play is you’ve And in segments that So market are we And in we know main we single two, well a large in the and a of as gone in to bioprocessing, molecule the [indiscernible] large technologies. activity very way bioprocessing, terms of the for and seen which more had use as as

growth in assumptions drive possible feel we of growth aggregate. the high the good growth good we enjoying outlook, end to that So because about about the and say for to market strong of our work I think and hard continue single-digit strength Biotech are to I we of market. would in When Pharma And highest the position will conditions.

Patrick Donnelly

Thank you. Okay.

Operator

Next Arias comes with from Citigroup. Dan question

Your line is open.

Daniel Arias

for just for sort you. back XXXX, coming Stephen, types track called much the you with EPS line of we a business? margin maybe Thank quarter seeing the guys. strategic how just morning, is last there commentary, impact on you're the that things the were if thought XXXX. trying of the to associated into out Is those from Good investments up extending the step number top of

Stephen Williamson

more think I we that approximately was QX when just guess, million investments. and I about investments up $XX over QX of step did,

the investments next where its includes think the and of businesses. all the basis expansion points right strategic whole across I of level XX year that about of year

up the level. additional step So kind XX to study in of separately. it's $XX end hard spending -- year investment million the of was [indiscernible] about There's

run the are of of more organic a more kind [indiscernible] -- tied normal growth. Now to rate

of investments each on give line the So the I expecting don’t but or going numbers given the it's in growth be in the for to spending level of an that strategic appropriate businesses specific we’re total, top year.

Daniel Arias

Thanks. that on shifting to the just option the had or just then of in manufacturing contingency And meaningful is just you. the production if terms way Thank escalate sort Marc, that at you of you maybe, in tariffs point around. have part offset of do further? Okay. this plans I’m is that have things in curious a

Marc N. Casper

So terms actions, actions, taken the taken tariffs, plans place some we tariffs permanent. pricing if in chain address supply incremental incremental we've have in really some and to remain we've of sourcing the the

at do, or easily know we a do of it I back we it So way. haven't we have what want its but it done lot But we move don't bunch can because this point would kind takes them activity, of and the which then of to that do. a

landscape seeing particular to figure the time more. weighing have be will what kind for and we we're on Operator, out of those So little one just bit actions. a

Operator

from And with Brennan UBS. question Daniel your comes last

open. line Your is

Daniel Brennan

the Thanks you. for quarter. question. Thank the on Congrats

and China, grow on there. us did can What quarter? was biopharma actually let 'XX for what know hoping you Marc, for So, maybe in specifically assumed just business I the your in

As from a [indiscernible] transition the understand are the generic towards countries it, therapeutic orientation focus. we

outlook? doing in your today is biopharma the business how So

Marc N. Casper

Yes.

like the It If XX%, different for This So over starting history, like quarter. point. we Feel we've was think XX% was think We're it in guidance. the that had a mid-teens quarter, XX% I was X% at that’s something a the embedded -- I reasonable for XX.X% -- had the assuming strong very on something assumption back growth. levels. year.

the mid-teens in share. year. we Remember, for feel and had one think but the points be the I about we good that others, more of double-digit had the outlook the we starting past in will bullish

Daniel Brennan

in terms biopharma your business Marc? And of there,

Marc N. Casper

good. really speakers] [Multiple

out medicines Chinese go been little years of country. drugs the extremely emergence it's five ago, than traditional coming innovative was you the of very given If medicine. and And there other robust

adds So that and we’ve that had to really good growth there also market. sustainability

thank I’ve updating you It's about always We So support of been more And to me course say Thanks forward your Fisher opportunities over excited for the a everyone. But we XXXX. ongoing the the are of look you to let wrap fantastic as Thermo call. up Scientific. ahead. year.

Operator

today’s conference concludes call. This

disconnect. now may You

Thermo Fisher Scientific (TMO) 30 Jan 192018 Q4 Earnings call transcript